Lincoln Pharmaceuticals Share Price
624.30+1.65 (+0.26%)
+12.40% past 1 Year
Lincoln Pharmaceuticals Ltd is engaged in the manufacture and marketing of affordable therapeutic products. The product range of the company includes Tablets ,Capsules,Injectables,Syrups and Ointments.
Corporate filings & documents
Announcements
The intimation of Book Closure and Record date is as enclosed.
5 days agoThe intimation of Book Closure and Record date is as enclosed.
5 days agoPursuant to Regulation 42 of SEBI (LODR) Regulations 2015 we would like to inform you that the 32nd Annual General Meeting of the Company is scheduled to be held on Wednesday September 30 2026 at 11:00 A.M (IST) through Video Conferencing ("VC") /Other Audio-Visual Means ("OVAM").
5 days agoPursuant to Regulation 42 of SEBI (LODR) Regulations 2015 we would like to inform you that the 32nd Annual General Meeting of the Company is scheduled to be held on Wednesday September 30 2026 at 11:00 A.M (IST) through Video Conferencing ("VC") /Other Audio-Visual Means ("OVAM").
5 days agoNewspaper Advertisement regarding the 32nd Annual General Meeting of the Company to be held on Wednesday September 30 2026.
1 week agoNewspaper Advertisement regarding the 32nd Annual General Meeting of the Company to be held on Wednesday September 30 2026.
1 week agoWe enclosed herewith the copies of newspaper intimation with respect to the unaudited (standalone & Consolidated) Financial Results of the Company for the Quarter Ended 30 June 2026.
3 weeks agoWe enclosed herewith the copies of newspaper intimation with respect to the unaudited (standalone & Consolidated) Financial Results of the Company for the Quarter Ended 30 June 2026.
3 weeks agoUn-Audited Financial Results For Quarter Ended on 30 June 2026.
3 weeks agoUn-Audited Financial Results For Quarter Ended on 30 June 2026.
3 weeks agoUn-Audited Financial Results of the Company For the Quarter Ended June 30 2026.
3 weeks agoUn-Audited Financial Results of the Company For the Quarter Ended June 30 2026.
3 weeks agoLincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve Lincoln Pharmaceuticals Ltd has Informed BSE that the meeting of the Board of Directors of the Company is Scheduled on 13/08/2026 Inter alia to consider and approve Unaudited standalone and consolidated financial results of the Company for the quarter ended on June 30 2026.
4 weeks agoLincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve Lincoln Pharmaceuticals Ltd has Informed BSE that the meeting of the Board of Directors of the Company is Scheduled on 13/08/2026 Inter alia to consider and approve Unaudited standalone and consolidated financial results of the Company for the quarter ended on June 30 2026.
4 weeks agoPursuant to provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation 2018 we hereby submit the confirmation certificate received from MUFG Intime India Private Limited Registrar and Share Transfer Agent (RTA) for the Quarter ended June 30 2026.
1 month agoPursuant to provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation 2018 we hereby submit the confirmation certificate received from MUFG Intime India Private Limited Registrar and Share Transfer Agent (RTA) for the Quarter ended June 30 2026.
1 month agoIntimation of Trading Window Closure for the Quarter ended June 30 2026.
2 months agoIntimation of Trading Window Closure for the Quarter ended June 30 2026.
2 months agoWe enclosed herewith the copies of published newspaper advertisement with respect to Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Year ended March 31 2026.
3 months agoRecommended a Final Dividend of Rs. 1.80/- (i.e 18%) per equity share of face value Rs. 10/- each for the financial year ended March 31 2026 subject to approval of the members at the ensuing Annual General Meeting of the Company.
3 months agoAudited Financial Results for the Quarter and Year ended March 31 2026.
3 months agoOutcome of Board Meeting for Audited Financial Results for the Quarter and Year Ended 31st March 2026.
3 months agoMeeting of the Board of Directors is scheduled to be held on May 28 2026 to consider and approve Audited Financial Results of the Company and recommendation of Dividend on equity shares of the Company if any.
3 months agoMeeting of the Board of Directors is scheduled to be held on May 28 2026 to consider and approve Audited Financial Results of the Company and recommendation of Dividend on equity shares of the Company if any.
3 months agoLincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 inter alia to consider and approve Audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31 2026.
3 months agoLincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 inter alia to consider and approve Audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31 2026.
3 months agoAnnual Secretarial Compliance Report for the financial year ended March 31 2026.
3 months agoCopies of Newspaper Advertisement as required under Rule 6 of IEPF Authority (Accounting Audit Transfer and Refund)Rules 2016 and amendments thereof.
3 months ago<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Lincoln Pharmaceuticals Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24230GJ1995PLC024288</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2025-26 2026-27</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2025-26 2026-27</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Trusha Shah</td></tr><tr><td>Designation :-</td><td>Company Secretary and Compliance Officer</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Darshit Shah</td></tr> <tr><td>Designation : -</td><td>Chief Financial Officer</td></tr></table><div> <br/> Date: 05/05/2026<br/><br/></div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Lincoln Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230GJ1995PLC024288</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: TRUSHA SHAH <br/> Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: DARSHIT SHAH <br/> Designation: CHIEF FINANCIAL OFFICER <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 16/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Lincoln Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230GJ1995PLC024288</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: TRUSHA SHAH <br/> Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: DARSHIT SHAH <br/> Designation: CHIEF FINANCIAL OFFICER <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 16/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoPursuant to Provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation 2018 We hereby submit the confirmation Certificate received from MUFG Intime India Private Limited Registrar and Share Transfer Agent (RTA) for the Quarter ended March 31 2026.
5 months agoPursuant to Provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation 2018 We hereby submit the confirmation Certificate received from MUFG Intime India Private Limited Registrar and Share Transfer Agent (RTA) for the Quarter ended March 31 2026.
5 months agoIntimation of Closure of Trading Window.
5 months agoPursuant to Regulation of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 we attach herewith transcript of conference call held on February 18 2026. A copy of the same is available on website of the company.
6 months agoWe wish to inform you that the Company participated in investor conference- Call Conference on February 18 2026. No Unpublished Price Sensitive Information (UPSI) was shared / discussed in the meeting with investors.
6 months agoIntimation of Schedule of earnings conference call to discuss the unaudited Financial Results of the Company for the quarter and nine months ended 31st December 2025.
6 months agoIntimation of Schedule of earnings conference call to discuss the unaudited Financial Results of the Company for the quarter and nine months ended 31st December 2025.
6 months agoNewspaper Advertisement with respect to unaudited financial results (Standalone & Consolidated) for the quarter and nine months ended on December 31 2025.
6 months agoUnaudited Financial Results of the Company for the Quarter and Nine Months ended on 31.12.2025.
6 months agoOutcome of the meeting held today
6 months agoLincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 inter alia to consider and approve unaudited Financial Results (Standalone And Consolidated) Of The Company For The Third Quarter And Nine Months Ended 31st December 2025 And Other Business if any.
7 months agoUpdate on Credit Rating.
7 months agoPursuant to provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation 2018 we hereby submit the confirmation certificate received from MUFG Intime India Private Limited Registrar and Share Transfer Agent (RTA) for the Quarter ended December 31 2025.
8 months agoIntimation of Closure of Trading Window
8 months agoPursuant to Regulation 47 of SEBI (LODR) Regulations 2015 we enclosed herewith the copies of newspaper intimation with respect to un-audited financial results for the quarter and half year ended on 30.09.2025.
9 months agoUN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2025
9 months agoUN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2025
9 months agoLincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter and Half Year ended 30.09.2025.
10 months agoWith reference to the above please find enclosed herewith the Minutes of 31st Annual General Meeting of the Company held at 11:00 A.M on Tuesday the 30th September 2025 through Video Conferencing ("VC")/ Other Audio-Video Visual Means (OVAM) to seek the approval of the members of the Company on resolutions set out in the Notice convening meeting.
10 months agoAnnual reports
Concalls & investor presentations
Feb 2026
ConcallPresentation
May 2024
ConcallPresentation
Feb 2023
ConcallPresentation
Nov 2022
ConcallPresentation
Aug 2022
ConcallPresentation
May 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Nov 2021
ConcallPresentation
Aug 2021
ConcallPresentation
May 2021
ConcallPresentation
Feb 2021
ConcallPresentation
Nov 2020
ConcallPresentation
Corporate Actions
Date
Type
Details
2026-09-11
Dividend
1.8
2025-09-12
Dividend
1.8
2024-09-13
Dividend
1.8
2023-09-15
Dividend
1.5
2022-09-15
Dividend
1.5
2020-03-05
Dividend
1.5
2019-09-19
Dividend
1.5
2018-09-19
Dividend
1.5
2017-09-21
Dividend
1.2
2016-09-23
Dividend
1.0
Company details
Registered office
Lincoln House", Behind Satyam Complex Science City Road Sola Ahmedabad Gujarat PIN: 380060 Tel No: 079-41078000 Fax No: 079-41078062 Email: [email protected] Internet: www.lincolnpharma.com
Registrars
506-508, 5th Floor, Amaranth Business Complex - I (ABC - I)Beside Gala Business Center, St. Xaviers Corner, Off C.G. Road,Navrangpura, Ahmedabad - 380009 506-508, 5th Floor, Amaranth Business Complex - I (ABC - I) Beside Gala Business Center, St. Xaviers Corner, Off C.G. Road Navrangpura PIN: Tel No: NULL Fax No: NULL Email: [email protected] Internet: https://in.mpms.mufg.com/
Management
Trusha Shah, Company Secretary & Compliance Officer
Kishor M Shah, Chairman
Mahendra G Patel, Managing Director
Hashmukhbhai Ishwarlal Patel, Whole Time Director
Munjal M Patel, Whole Time Director
Ashish Patel, Whole Time Director
Rajnikant G Patel, Non Executive Director
Seema Mehta, Non Executive Independent Director
Nareshkumar Suthar, Non Executive Independent Director
Saurin J Parikh, Non Executive Independent Director
Details
BSE 531633
NSE LINCOLN
ISIN INE405C01035